Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative Study

Favipiravir study #18 of 18 All Outcomes

8/24 Late treatment study

Almoosa et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.022 (Peer Reviewed)
Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative Study

Source PDF Share Tweet

Retrospective 226 COVID-19 pneumonia patients, 110 treated with favipiravir, showing higher mortality (p=0.1) and ICU admission (p=0.02) with treatment in multivariate analysis.

Almoosa et al., 8/24/2021, retrospective, Saudi Arabia, Middle East, peer-reviewed, 14 authors.

risk of death, 42.3% higher, RR 1.42, p = 0.10, treatment 33 of 110 (30.0%), control 24 of 116 (20.7%), adjusted per study, odds ratio converted to relative risk, overall mortality, multivariate binary logistic regression.

risk of ICU admission, 90.0% higher, RR 1.90, p = 0.02, treatment 110, control 116, adjusted per study, multivariate binary logistic regression, RR approximated with OR.

recovery time, 10.9% higher, relative time 1.11, p = 0.17, treatment 110, control 116.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 18 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit